HLA DR1/3/4/5, DQ Intermediate Resolution
Use
Detect Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma spp
Special Instructions
Not provided.
Limitations
This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary.
Methodology
Nucleic acid amplification (NAA)
Biomarkers
LOINC Codes
- 91134-7 - STI Pnl Spec NAA+probe
- 88226-6 - M genitalium DNA Ur Ql NAA+probe
- 68546-1 - M hominis DNA Spec Ql NAA+probe
- 68547-9 - Ureaplasma DNA Spec Ql NAA+probe
- 42931-6 - C trach rRNA Ur Ql NAA+probe
- 60256-5 - N gonorrhoea rRNA Ur Ql NAA+probe
- 57298-2 - HLA-DRB1
- 59022-4 - HLA-DRB3
- 59021-6 - HLA-DRB4
- 59020-8 - HLA-DRB5
- 53938-7 - HLA-DQB1
- 49549-9 - Ref lab test method
Result Turnaround Time
3-4 days
Related Documents
For more information, please review the documents below
Specimen
Unknown
Volume
Not provided
Minimum Volume
Not provided
Patient Preparation
The patient should not have urinated for at least one hour prior to specimen collection.
Causes for Rejection
Specimen with incorrect patient identification; unlabeled specimen; inappropriate specimen transport conditions; specimens received after prolonged delay (usually >72 hours); specimen leaked in transit; specimen in expired transport or incorrect transport device; specimens with inappropriate source for test requested; specimen with fixative or additives; Aptima® urine transport >30 days from collection; Aptima® urine transport with incorrect specimen volume; specimen in ProbeTec™ UPT transport; ProbeTec™ Q-swabs; urine in sterile container
Other tests from different labs that may be relevant